Non-Hodgkin lymphoma Posts Page 2 on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Right To Try: Needed Legislation or Snake Oil?

Right To Try: Needed Legislation or Snake Oil?

Posted by on Mar 10, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process.  There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...

Read More

What are the long-term outcomes after plerixafor and G-CSF before stem cell transplantation?

Posted by on Mar 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...

Read More

Which chemotherapies increase the risk of developing pneumonitis in non-Hodgkin lymphoma?

Posted by on Mar 7, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looks at how often patients being treated for non-Hodgkin lymphoma develop pneumonitis, a swelling of the lungs. The study concluded that patients being treated with R-CDOP chemotherapy are at the highest risk of developing pneumonitis.  Some background Pneumonitis is a dangerous and potentially deadly swelling of the...

Read More

Does PET/CT scanning during chemotherapy improve IPI-based outcome predictions for DLBCL patients?

Posted by on Feb 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether interim FDG PET/CT scanning during chemotherapy helps predict risk for new DLBCL (diffuse large B-cell lymphoma) patients. This study concluded that this scanning improves the risk classifications used to predict outcomes for DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most...

Read More

Does liposomal doxorubicin improve heart side effects in lymphoma patients compared to conventional doxorubicin?

Posted by on Feb 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the impact of liposomal doxorubicin (Adriamycin) on cardiac side effects in lymphoma patients compared to conventional doxorubicin. The study suggested that liposomal doxorubicin can reduce cardiac effects and still be an effective therapy, particularly for patients at high risk for anthracycline-induced...

Read More

Chemotherapy followed by radio-immunotherapy to treat patients with mantle cell lymphoma

Posted by on Feb 16, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of chemotherapy followed by a single dose of radio-immunotherapy for treating patients with mantle cell lymphoma. The study concluded that radio-immunotherapy after standard chemotherapy is safe and effective to treat patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL)...

Read More

Timing of allogenic stem cell transplantation in patients with relapsed follicular lymphoma

Posted by on Feb 16, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the outcomes of patients with relapsed follicular lymphoma who were treated with allogeneic stem cell transplantation. The authors concluded that allogeneic stem cell transplantation is an effective treatment, and is most effective when treating earlier phases of the disease.  Some background Follicular...

Read More

Does consolidative radiotherapy improve survival in DLBCL patients?

Posted by on Feb 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the medical records of DLBCL patients who received consolidative radiotherapy (RT) after chemotherapy to determine if consolidative RT improved survival. This study concluded that consolidative RT might improve survival in DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...

Read More

Combined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?

Posted by on Jan 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...

Read More

To Treat or Not To Treat Cancer: Medical Decision-making

To Treat or Not To Treat Cancer: Medical Decision-making

Posted by on Jan 28, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma | 7 comments

Cherry Hughes** is an active, energetic 75 year old, still working in the marketing and public relations profession in Great Britain.  Her life is filled with friends and fun.  “I love cooking and eating out.  I am deeply interested in politics.  I love music …I go to jazz clubs.  I love going to France …I have a little apartment...

Read More

How many scans? Effectiveness of surveillance PET or CT scans for detecting relapse in patients after autologous stem cell transplantation

Posted by on Jan 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effect of surveillance scans after autologous stem cell transplantation (auto-SCT) in patients with relapsed or refractory diffuse large B-cell lymphoma. The study concluded that scanning everyone after auto-SCT has little benefit.  Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...

Read More

What are the outcomes of reduced intensity alloSCT in MCL patients?

Posted by on Jan 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of MCL (mantle cell lymphoma) patients who received RIST (reduced-intensity allogenic stem cell transplant) therapy. The authors concluded that RIST may be curative in MCL patients, even in those who relapsed after autoSCT (autologous stem cell transplant). Some background Mantle cell...

Read More